We hypothesized that a higher efficacy at reducing LN tumor burden would be achieved by a neutralizing anti-CCR7 monoclonal antibody (mAb) able to immobilize cancer cells and to elicit cell killing (52, 62, 63). Here, CCR7 is linked to cancer.